Thromboprophylaxis
We recommend
Biosimilars in the Prophylaxis of Venous Thromboembolism
Nízkomolekulární hepariny jsou zlatým standardem antitrombotické profylaxe u chirurgických i interních pacientů. Od roku 2016 je v EU registrován první biosimilární enoxaparin – Inhixa. Italská studie přináší výsledky hodnocení jeho účinnosti a bezpečnosti v prevenci žilní tromboembolie v reálné klinické praxi i jejich porovnání se sdruženými daty u srovnatelné populace pacientů z klinických studií s originálním enoxaparinem.
Potential of Enoxaparin to Maintain A-V Shunt Patency According to the SEP Protocol
A newly published study by authors from Singapore focused on the ability of the SEP protocol –…
How to Navigate the Challenges of Anticoagulant Therapy in Pregnant Women − A Case Study
Every carrier of a mechanical heart valve is also on anticoagulant therapy. Warfarin is most…
Articles on this topic
Thromboprophylaxis in Cancer Patients − Results of Current Meta-Analysis
A recently published meta-analysis shows the benefits of thromboprophylaxis in cancer…
Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?
A study published this year aimed to assess how often the risk of VTE is assessed in routine…
Insufficient dosing of enoxaparin is common in patients post-orthopedic surgery and increases the risk of thromboembolic disease
Orthopedic and traumatological procedures involving the pelvis and lower limbs are associated…
Type of Pharmacological Thromboprophylaxis and Disease Stage as Risk Factors for Bleeding in Patients After Colorectal Cancer Surgery
Japanese authors of a study published last year in the World Journal of Surgical Oncology…
Low-Molecular-Weight Heparin as Adjuvant Therapy in Small-Cell Lung Cancer − Results of the RASTEN Study
Several studies and meta-analyses in the past have pointed to a possible positive effect of…
How to Manage Thromboprophylaxis in Obese and Extremely Obese Patients?
Doctors often address the question of how to dose thromboprophylaxis in overweight…
Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients
Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized…
Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity
Oncological patients undergoing surgical procedures are observed to have a high risk of…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Different doses of LMWH in hospitalized patients with COVID-19 – interim experience
- Low-Molecular-Weight Heparins in Thromboprophylaxis After Major Orthopedic and Traumatological Procedures According to Current Recommendations
- How to Manage Thromboprophylaxis in Obese and Extremely Obese Patients?
- Anticoagulants and Antiplatelets in the Treatment of Acute Coronary Syndromes
- Administration of Low-Molecular-Weight Heparin After Hemorrhagic Stroke: What Is the Appropriate Timing?
- Thromboprophylaxis with Enoxaparin Reduces Mortality in Patients Hospitalized with COVID-19
Journal on this topic
Related topic